Rebecca M. Edelmayer, Ph.D., is a distinguished neuroscientist and pharmacologist, currently serving as Vice President of Scientific Engagement at the Alzheimer's Association®. She earned her Ph.D. in Medical Pharmacology from the University of Arizona and a bachelor’s degree in Neuroscience from the University of Pittsburgh.

Dr. Edelmayer's career spans significant contributions across non-profit, academic, and industry sectors, including senior scientific roles at AbbVie and Abbott. With extensive experience as a scientist and educator, she unites researchers and clinicians on topics related to neurodegenerative diseases, biomarker testing, drug discovery, clinical trials, and real-world evidence studies. Her leadership continues to drive advancements in dementia research and treatment, making a profound impact on the field.

At the Alzheimer’s Association, Dr. Edelmayer leads several national and international initiatives in dementia science. She is a study investigator for the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET), a real-world data initiative for new FDA-approved Alzheimer’s therapies. She oversees the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART), an inclusive global network of over 13,000 researchers, clinicians and dementia professionals. Her team continues to expand the Association’s suite of global scientific meetings where theories, breakthroughs and best practices can be shared. This includes the Alzheimer’s Association International Conference® (AAIC®), the largest and most influential international meeting dedicated to advancing dementia science. She supports the Association’s commitment to disseminating scientific and medical knowledge through Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association and its family of companion journals to advance understanding of Alzheimer's and all other dementia.

She serves on steering committees and advisory boards for cutting-edge scientific consortia established by the National Institute on Aging to advance biomarker and treatment development, including AMP-AD, MODEL-AD and TREAT-AD.

Dr. Edelmayer is dedicated to advancing the Alzheimer’s Association’s scientific agenda through research education and community engagement. She engages with chapters across the country, ensuring that communities are informed of the global progress of dementia science and the organization’s crucial role in advancing research to improve the lives of those facing Alzheimer’s and all other dementia.